Related Experiment Video
Updated: Jun 27, 2026
08:28
Microsurgical Skills of Establishing Permanent Jugular Vein Cannulation in Rats for Serial Blood Sampling of Orally Administered Drug
Published on: December 14, 2021
Pharmacologic characterization of meloxicam
1Department of Pulmonary Research, (Atemwegsforschung), Boehringer Ingelheim Pharma KG, Ingelheim, Germany.
Summary
Meloxicam preferentially inhibits cyclooxygenase-2 (COX-2), offering a potentially safer alternative to other nonsteroidal anti-inflammatory drugs (NSAIDs). This COX-2 sparing effect may improve gastrointestinal and renal safety, with potential applications in Alzheimer's disease and colorectal cancer.
Area of Science:
- Pharmacology
- Inflammation Research
- Drug Discovery
Background:
- Nonsteroidal anti-inflammatory drugs (NSAIDs) mechanism of action was initially attributed to cyclooxygenase (COX) inhibition.
- Meloxicam demonstrated a unique pharmacologic profile compared to other NSAIDs, which lacked a clear explanation.
- The discovery of COX-2 provided a hypothesis for meloxicam's distinct properties.
Purpose of the Study:
- To investigate meloxicam's mechanism of action in relation to COX enzymes.
- To explore the in vivo effects of meloxicam's preferential COX-2 inhibition.
- To assess the potential therapeutic benefits of meloxicam beyond inflammation.
Main Methods:
- In vitro testing to determine meloxicam's inhibitory activity against COX-1 and COX-2.
- In vivo pharmacologic studies in animal models and human subjects.
- Analysis of gastrointestinal and renal safety profiles associated with meloxicam use.
Main Results:
- Meloxicam demonstrated consistent preferential inhibition of COX-2 in vitro.
- Pharmacologic studies confirmed a COX-1 sparing effect in vivo.
- Improved gastrointestinal and renal safety profiles were observed and linked to COX-2 sparing.
Conclusions:
- The COX hypothesis is a valid estimator of NSAID efficacy and safety, exemplified by meloxicam.
- Meloxicam's COX-2 sparing effect contributes to its improved safety profile.
- Further research into meloxicam's potential roles in Alzheimer's disease and colorectal cancer is warranted.
Related Concept Videos
01:24Cholinergic Antagonists: Pharmacokinetics
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:11Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics
All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
01:29Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...